Behringwerke Aktiengesellschaft

Previpharma Consulting Gmbh

Achim Becker

Gerd Zettlmeibl

Hermann E. Karges

Hermann Erich Karges

Norbert Heimburger

Gerd Zettlmeissl

Volker Teetz

Rolf Geiger

Hans-Harald Sedlacek

Gerhardt Kumpe

Wilfried Wormsbacher

Helmut Heber

Rainer Uhmann

Horst Naumann

Fritz Seiler

Eckart Jacobi

Roloff Johannsen

Hanne Rieke Gerding

Marc Mazur

Stephan T Kiessig

Ricarda Welz

The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.

Preparing and use of Glu-plasminogen from blood fractions

The invention relates to a process for producing a virus free preparation of thrombin, and the use of said virus free concentrate as a pharmaceutical. For example, the invention relates to a process for the production of a purified and virus free preparation of thrombin which comprises adding a soluble salt in a concentration of from 0.5 mol/l up to the saturation limit thereof, said soluble salt having an anion that forms a sparingly-soluble salt or a soluble complex with calcium, to a solution of a prothrombin complex which has been purified on an anion exchanger and subjected to virus inactivation, said solution having a catalytic amount of thrombin present as a result of the purification, the viral inactivation, or added thereafter at a concentration of greater than zero up to 200 units of thrombin per ml of solution.

Process for the production of a virus-free concentrate of thrombin

Mutants of AT III which have been advantageously modified at one or more potential glycosylation sites or at the Arg393 position are described. As a rule, combination of the mutations enhances the advantageous modifications.

Mutants of human antithrobin III and methods for their production

Mutants of human antithrombin III

A process for the preparation of a pasteurized human citrated plasma is described, in which citrated plasma, from which the prothrombin factors and labile proteins have been removed, is heated in the presence of stabilizers.

Process for the pasteurization of human residual plasma

What are disclosed are chromogenic peptides useful as substrates for the detection and determination of enzymes having a hydrolytic action and methods for detecting and determining enzymes with such peptides.

Chromogenic compounds and their use as enzyme substrates

The invention provides tanned thrombocytes, a process for preparing them and a diagnostic agent containing them to make evident antibodies of thrombocytes.

Tanned thrombocytes

Antithrombin III in plasma or serum is determined by combining diluted plasma or serum with heparin or heparinoids and thrombin to form a mixture, permitting the mixture to stand, thereafter adding to the mixture a fibrinogen solution and determining the coagulation time. The heparin or heparinoids and thrombin can be combined together to form a reagent for use in the determination.

Quantitative determination of antithrombin III

The invention relates to a process for the analytical determination of human plasminogen which comprises mixing a liquid containing diluted human plasminogen with

Process for the determination of plasminogen

Substrate for determining proteinases wherein a substrate protein is bound by a covalent bond in fine distribution in or on the surface of a solid carrier and dyed with a reactive dyestuff, its manufacture and its use.

Growing community of inventors

Marburg, Germany

Hermann Erich Karges